Trials / Completed
CompletedNCT03214367
A Study of LY900014 in Participants With Type 1 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro With an Open-Label Postprandial LY900014 Treatment Group, in Combination With Insulin Glargine or Insulin Degludec, in Adults With Type 1 Diabetes PRONTO-T1D
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,392 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy of the study drug LY900014 compared to insulin lispro, both in combination with insulin glargine or insulin degludec, in adults with type 1 diabetes (T1D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY900014 | Administered SC |
| DRUG | Insulin Lispro | Administered SC |
| DRUG | Insulin Glargine | Administered SC |
| DRUG | Insulin Degludec | Administered SC |
Timeline
- Start date
- 2017-07-17
- Primary completion
- 2018-09-06
- Completion
- 2019-08-22
- First posted
- 2017-07-11
- Last updated
- 2020-05-01
- Results posted
- 2020-05-01
Locations
172 sites across 20 countries: United States, Argentina, Australia, Austria, Brazil, Germany, Greece, India, Italy, Japan, Mexico, New Zealand, Poland, Puerto Rico, Romania, Russia, Slovakia, Spain, Sweden, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03214367. Inclusion in this directory is not an endorsement.